

CombiGene invites analysts and shareholders to the company's presentation at Aktiespararna's digital event on October 19

On Monday 19 October at 10.30, CEO Jan Nilsson and Chief Research & Development Officer Karin Agerman will present at Aktiespararna's digital event. CombiGene hereby invites analysts and shareholders to a comprehensive presentation of CombiGene's latest advances in the epilepsy project CG01 and the fantastic opportunities that this project holds.

<https://www.aktiespararna.se/aktiviteter/aktiedagen-digitalt-19-oktober-2020>

Contacts

Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the board
Phone: +46 (0)707 77 22 09
bert.junno@combigene.com

www.combigene.com
CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com

About CombiGene

CombiGene's vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.

CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

CombiGene's lead project CG01 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282

Press Release
15 October 2020 08:45:00 CEST



Attachments

[CombiGene invites analysts and shareholders to the company's presentation at Aktiespararna's digital event on October 19](#)